Surgery after EGFR TKI shows promise in prolonging progression-free survival in metastatic NSCLC

Published Date: 10 Sep 2025

A randomized Phase II trial from National Taiwan University Hospital reports early evidence that resecting the primary thoracic tumor following EGFR tyrosine kinase inhibitor (TKI) therapy may prolong disease control in patients ...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

unhealthy sleeping habits and the risk of esophageal adenocarcinoma.

2.

Positive Trials; Malignancies Increasing in Younger Adults; Andre Braugher's Cancer Dx.

3.

Response Duration After Stopping Enfortumab Vedotin in Bladder Cancer

4.

In myelofibrosis, combinations of rufolitinib reduce spleen volume.

5.

Radioactive ion beams successfully treat animal tumors in study


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot